Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease (I8G-MC-LMDC)

Eli Lilly Japan K.K.0 个研究点目标入组 360 人开始时间: 2018年6月14日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Participants must have gradual and progressive change in memory function for >6 months.
•- Participants must have a family member or close friend who is with you at least 10 hours per week and can attend study appointments.

•- Participants must not have significant neurological disease affecting the nervous system, other than AD, that affects cognition or may affect completion of the study.
•- Participants must not have serious or unstable illness that could interfere with the analysis of the study or has a life expectancy <24 months.
•- Participants must not have history of cancer within the last 5 years with the exception of certain types of skin, cervical, prostate, and other cancers that are not likely to recur or spread.
•- Participants must not have serious risk for suicide.
•- Participants must not have history of drug or alcohol use disorder within the last 2 years.
•- Participants must not have multiple severe drug allergies
•- Participants must not have HIV, Hepatitis B or Hepatitis C
•- Participants must not be receiving gamma globulin (IgG) or intravenous immunoglobulin (IVIG) therapy

发起方